TY - JOUR
T1 - Apolipoprotein M and its impact on endothelial dysfunction and inflammation in the cardiovascular system
AU - Yao Mattisson, Ingrid
AU - Christoffersen, Christina
N1 - Publisher Copyright:
© 2021 The Authors
PY - 2021
Y1 - 2021
N2 - Apolipoprotein M (apoM) is a member of the lipocalin superfamily and is predominantly associated with high-density lipoprotein (HDL). It was found that apoM is the chaperon to the bioactive sphingolipid, sphingosine-1-phosphate (S1P). Several studies have since contributed to expand the knowledge on apoM, S1P, and the apoM/S1P-complex in cardiovascular diseases. For instance, the HDL-bound apoM/S1P complex serves as a bridge between HDL and endothelial cells, maintaining a healthy endothelial barrier. Evidence indicates, however, that the apoM/S1P complex may has both protective and harmful effects on the cardiovascular system, which suggests the need for more research to understand the interplay between these molecules. This review aims to shed light on the most recent findings on apoM/S1P-signaling and its impact on endothelial dysfunction, inflammation, and cardiovascular diseases. Finally, it will be discussed whether drugs that target apoM and/or S1P-signaling may be beneficial to patients with cardiovascular and inflammatory diseases.
AB - Apolipoprotein M (apoM) is a member of the lipocalin superfamily and is predominantly associated with high-density lipoprotein (HDL). It was found that apoM is the chaperon to the bioactive sphingolipid, sphingosine-1-phosphate (S1P). Several studies have since contributed to expand the knowledge on apoM, S1P, and the apoM/S1P-complex in cardiovascular diseases. For instance, the HDL-bound apoM/S1P complex serves as a bridge between HDL and endothelial cells, maintaining a healthy endothelial barrier. Evidence indicates, however, that the apoM/S1P complex may has both protective and harmful effects on the cardiovascular system, which suggests the need for more research to understand the interplay between these molecules. This review aims to shed light on the most recent findings on apoM/S1P-signaling and its impact on endothelial dysfunction, inflammation, and cardiovascular diseases. Finally, it will be discussed whether drugs that target apoM and/or S1P-signaling may be beneficial to patients with cardiovascular and inflammatory diseases.
KW - Apolipoprotein M
KW - Cardiovascular disease
KW - Endothelial dysfunction
KW - Inflammation
KW - Lipid metabolism
KW - Sphingosine-1-phosphate
UR - http://www.scopus.com/inward/record.url?scp=85114364006&partnerID=8YFLogxK
U2 - 10.1016/j.atherosclerosis.2021.08.039
DO - 10.1016/j.atherosclerosis.2021.08.039
M3 - Review
C2 - 34482091
AN - SCOPUS:85114364006
VL - 334
SP - 76
EP - 84
JO - Journal of atherosclerosis research
JF - Journal of atherosclerosis research
SN - 1567-5688
ER -